De Novo Malignant Eccrine Spiradenoma: A Case Report and Review of the Literature

Hantash, Basil M.; Chan, Joanna L.; Egbert, Barbara M.; Gladstone, Hayes B.

doi:10.1111/j.1524-4725.2006.32265.x

Cited by 25 publications

(38 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Longstanding lesions rarely enlarge rapidly with ulceration or change of color to progress to a malignant eccrine spiradenoma (MES). MES is rare, with only 98 cases reported to date [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16]. Here we describe a unique case of MES that metastasized to an intramammary lymph node (IMLN).…”

Section: Introductionmentioning

confidence: 85%

A case of malignant eccrine spiradenoma metastatic to intramammary lymph node

2008

View full text Add to dashboard Cite

Eccrine spiradenoma (ES) is a fairly common, benign, cutaneous tumor originating from the sweat glands. In contrast, the malignant counterpart of ES, malignant eccrine spiradenoma (MES), is extremely rare. A long-standing lesion rarely begins to enlarge rapidly. A growth that results in ulceration or discoloration may be associated with malignant transformation. We present the first reported case of this tumor metastasizing to an intramammary lymph node (IMLN). The uncommon metastasizing focus of the periumbilical MES and its histopathological similarity with a primary breast carcinoma made the diagnosis difficult.

show abstract

Section: Introductionmentioning

confidence: 85%

A case of malignant eccrine spiradenoma metastatic to intramammary lymph node

2008

View full text Add to dashboard Cite

show abstract

“…In their report, 45 of the 96 patients with MES had no recurrence, whereas it developed in 32 patients. On the other hand, 19 had no data available about recurrence [5]. Similarly, in a paper including 16 Japanese patients with MES, recurrence did not occur in most of these cases [4].…”

Section: Discussionmentioning

confidence: 97%

“…Lymph node dissection is an effective method of treatment in the presence of lymph node metastases. Non-surgical treatments, including chemotherapy, radiotherapy and hormonal therapies, remain limited with only anecdotal evidence to support their efficacy [5]. Therefore, treatment of patients with visceral metastases is difficult, and mortality in these patients is extremely high.…”

Section: Discussionmentioning

confidence: 99%

“…Malignant eccrine spiradenoma (MES) is one of the extremely rare sweat gland tumours and often arises from benign eccrine spiradenoma or, less commonly, may develop de novo [1,3]. Transformation into malignant form generally occurs 20 to 30 years after initial detection, with a latency period ranging from 6 to 70 years [3][4][5]. Malignant eccrine spiradenoma occurs predominantly in older patients regardless of the ethnic group, with a slight female predominance [4,5].…”

Section: Introductionmentioning

confidence: 99%

“…Transformation into malignant form generally occurs 20 to 30 years after initial detection, with a latency period ranging from 6 to 70 years [3][4][5]. Malignant eccrine spiradenoma occurs predominantly in older patients regardless of the ethnic group, with a slight female predominance [4,5]. It sometimes develops in young patients [6,7].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

De novo malignant eccrine spiradenoma and metachronous lung cancer

Ünal¹,

Taşdemi̇r²,

Oguz³

et al. 2014

View full text Add to dashboard Cite

Malignant eccrine spiradenoma is an extremely rare sweat-gland tumour. Herein we aimed to present an 81-yearold woman with malignant eccrine spiradenoma repeated on the thigh and metachronous lung cancer. She presented with a palpable swelling in the right thigh region. Her systemic screening was normal and excisional biopsy was performed. A diagnosis of malignant eccrine spiradenoma was made. Thirty-two months later, the tumour recurred in the same region. The tumour was excised again. Lymph node metastasis was also detected in lymph node dissection. Fifteen months later, the tumour recurred again in the same place. In addition, lymph node metastasis and bone metastasis were found. Palliative radiotherapy was performed for the involvement of the right femur. The treatment for metachronous lung cancer could not be given because of the patient's age and performance, and she could not be given additional treatment for the same reasons.

show abstract

Appendageal Carcinomas and Cutaneous Sarcomas

Schwartz¹

2008

Skin Cancer

View full text Add to dashboard Cite

De Novo Malignant Eccrine Spiradenoma: A Case Report and Review of the Literature

Cited by 25 publications

References 50 publications

A case of malignant eccrine spiradenoma metastatic to intramammary lymph node

A case of malignant eccrine spiradenoma metastatic to intramammary lymph node

De novo malignant eccrine spiradenoma and metachronous lung cancer

Appendageal Carcinomas and Cutaneous Sarcomas

Contact Info

Product

Resources

About